Etanercept Drug Profile

Boxed warning

Serious infections
Lymphoma and other malignancies in children and adolescents

Clinical alerts

Boxed warning

2 boxed warnings

Mechanism of action

Fusion protein (TNF receptor + IgG1 Fc) that binds and inactivates TNF-alpha

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Rheumatoid Arthritis
·Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
·Juvenile Idiopathic Arthritis
·Moderate-to-severe Chronic Plaque Psoriasis
·Psoriasis

Interactions

No curated interaction pairs are recorded for Etanercept. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Injection site reactions
Infections
Headache
Rhinitis

Food, alcohol & herbal

Alcohol · minor

No significant interaction

Herbal

Echinacea (major) — May interfere with immunosuppression

Pharmacokinetics

Published parameters · PMID:15622968

Half-life: 102 hours
Protein binding: N/A
Metabolised by: Proteolytic degradation
Clearance: 0.066 L/h; adult rheumatoid arthritis patients
Volume of distribution: 7.6 L
Bioavailability: 58%
Renally eliminated: 0%
Model: 1-compartment

Pregnancy & lactation

Not recorded for Etanercept. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.